This book concisely covers the latest developments in the application of direct oral anticoagulants (DOACs) within cardiovascular medicine. It details the pharmacodynamics and pharmacokinetic mechanisms of DOACs and their application in treating patients with conditions ranging from coronary heart disease through kidney disease and cancer, including their perioperative management. Direct Oral Anticoagulants: From Pharmacology to Clinical Practice systematically describes the underlying mechanisms associated with DOACs and their use to treat a range of conditions and is an indispensable resource for all trainee and practicing physicians in a range of disciplines seeking a concise up-to-date resource on the topic.

Showcasing the expertise of top-tier specialists who contributed to the newly released guidelines for the care of thrombosis in cancer patients, this exciting guide was written and edited by members of the American Society of Clinical Oncology panel, (ASCO), on the prevention and treatment of cancer-associated thrombosis, among others, and provides

This book presents the latest evidence and guidelines supporting the use of anticoagulant therapy for various clinical scenarios. The field of anticoagulation therapy is evolving rapidly, particularly since the arrival and widespread adoption of direct oral anticoagulants. Organized in two parts, this book reviews the pharmacologic properties of various anticoagulants and details the clinical applications of anticoagulant therapy. Drugs such as warfarin and unfractionated heparin, as well as parenteral and direct oral anticoagulants are discussed in terms of their pharmacokinetics, drug-disease interactions, dosing strategies, and risk considerations. Clinical applications of anticoagulant therapy in disorders such as acute coronary syndromes, atrial fibrillation, and thrombophilia and in special populations such as pregnant women, the elderly, and in the patient with cancer are highlighted. Clinical vignettes, algorithms, clinical pearls, and self-assessment questions are integrated throughout the book. Featuring contributions from authorities in the field, Anticoagulation Therapy is an essential resource for cardiologists, vascular medicine specialists, hematologists, internists, and all other healthcare professionals who prescribe anticoagulants.

Anticoagulant drugs are among the most frequently prescribed drugs in everyday clinical practice. In the past decades, several new direct oral anticoagulants were developed that changed the anticoagulant therapy landscape considerably. This book provides an extensive overview of all the known anticoagulants that can be useful for studying different aspects of the haemostatic system or as a starting point for new drug development. It is also a valuable tool for clinicians providing a description of the mode of action and management of therapy for anticoagulant drugs used in everyday clinical practice in different clinical settings, including direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban.

All anesthesiologists are confronted with patients who show bleeding disorders, whether congenital, acquired, or pharmacologically induced. Although many studies, meta-analyses, guidelines, and textbooks have been published on the subject, they mostly cover specific aspects or require a thorough knowledge of hemostasis. The goal of this book is to provide the anesthesiologist with an overview of hemostasis and the mechanisms underlying bleeding and coagulation in general and to assist in the understanding of specific coagulation disorders as they may occur in the various anesthesia subspecialties. It is hoped that, through the provision of practical information and tools, the book will help residents and trained anesthesiologists to manage one of the most frustrating challenges that they face: the bleeding patient. A full understanding of coagulation requires a lifelong career, and this book is not intended to replace the consulting hematologist, whose expert opinion should always be sought. The available procoagulant blood products and drugs all have potentially dangerous side-effects; furthermore, in bleeding disorders pitfalls are frequent and a misdiagnosis can have potentially catastrophic consequences. The aim of the editors is thus instead to enhance the collaboration between the disciplines of Anesthesiology and Hematology.

Get a quick, expert overview of stroke risks among patients with treated and untreated atrial fibrillation, in addition to best practices for management and treatment of patients with atrial fibrillation to minimize stroke risks. This concise, clinically-focused resource by Dr. Greg Flaker consolidates today's available information on this timely topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee cardiologists as well as general practitioners treating and monitoring these patients. - Covers a broad spectrum of management and treatment options for atrial fibrillation including anticoagulants, surgical and implanted devices. - Presents information on recent drug trials to keep you up to date with the latest developments. - Includes guidance on anticoagulation in special situations, such as cardioversion and ablation, in addition to atrial fibrillation treatment in patients with other medical conditions including cancer, major bleeding disorders, and renal or liver disease. - Chapter on Risk Stratification assists in identifying patients with a high risk of stroke and predicting treatment outcomes. - Chapter on The New Anticoagulation Clinic overviews best practices for patient education, compliance, follow-up monitoring, and quality assurance to aid in better patient outcomes.

Clinical application of antithrombotic therapy in both arterial disease (acute coronary syndromes, acute MI, peripheral arterial disease, valvular heart disease, atrial fibrillation) and venous disease, (venous thromboembolic disease and pulmonary embolism). Results of major clinical trials and their implications for clinical practice.